Showing 4051-4060 of 6590 results for "".
- Medicaid Patients May Receive Less Timely Melanoma Surgeryhttps://practicaldermatology.com/news/medicaid-patients-may-receive-less-timely-melanoma-surgery/2458028/Delays in melanoma surgery may vary by insurance type, according to research in JAMA Dermatology. While Medicaid patients had the highest likelihood of delays, significant pro
- Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AKhttps://practicaldermatology.com/news/update-from-dfb-soria-on-enrollment-in-phase-2-clinical-trial-of-nanoparticle-paclitaxel-ointment-for-ak/2458039/DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, completed the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle
- Sciton and the Young Survival Coalition Partner for Breast Cancer Awarenesshttps://practicaldermatology.com/news/sciton-and-the-young-survival-coalition-partner-for-breast-cancer-awareness/2458041/Sciton, Inc.’s Women's Health Group division and the Young Survival Coalition (YSC) are partnering to raise awareness about women's vaginal health, in particular, those who are recovering from breast can
- EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe ADhttps://practicaldermatology.com/news/eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad/2458050/Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (C
- Vanda's Tradipitant Improves Itch and Disease Severity in AD Patientshttps://practicaldermatology.com/news/vandas-tradipitant-improves-itch-and-disease-severity-in-ad-patients/2458053/Vanda Pharmaceuticals Inc.’s tradipitant improved the intensity of the worst itch patients experienced, as well as atopic dermatitis (AD) disease severity, according to results from an eight-week randomized Phase 2 clinical. Tradipitant
- FDA Approves T.R.U.E. Test Ready-To-Use Patch Test for Pediatric Usehttps://practicaldermatology.com/news/fda-approves-true-test-ready-to-use-patch-test-for-pediatric-use/2458057/The FDA has approved SmartPractice's T.R.U.E. TEST (truetest.com) ready-to-use patch test panels for pediatric patients as young as 6 years of age. T.R.U.E. TEST is the only FDA-approved product for diagnosing allergic contact derm
- Bioré Skincare Partners with Girl Uphttps://practicaldermatology.com/news/bior-skincare-partners-with-girl-up/2458081/To celebrate the launch of their new Limited Edition Deep Cleansing Pore Strips, Bioré® Skincare is partnering with Girl Up™, a United Nations Foundation campaign. Girl Up mobilizes girls and women across the globe to raise awareness and funds for United Nations prog
- PuraCap Pharmaceuticals Introduces EpiCeram Quad Packhttps://practicaldermatology.com/news/puracap-pharmaceuticals-introduces-epiceram-quad-pack/2458088/PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which contains four 100-gram airless pumps. EpiCeram® is a US Food and Drug Administration-approved topical prescription e
- Cutanea Life Sciences Unveils Facing Forward Mobile App for Acne Patientshttps://practicaldermatology.com/news/cutanea-life-sciences-unveils-facing-forward-new-mobile-app-for-acne-patients/2458104/Cutanea Life Sciences, Inc. introduced its Facing Forward mobile application for patients who are prescribed Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The app will be available free thro
- Simulation Techniques Help Medical Students Empathize with Melanoma Patientshttps://practicaldermatology.com/news/simulation-techniques-help-medical-students-empathize-with-melanoma-patients/2458110/Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the